Regulation of novel protein kinase C epsilon by phosphorylation.

Boston Biomedical Research Institute, Watertown, MA 02472, USA.
Biochemical Journal (Impact Factor: 4.78). 06/2002; 363(Pt 3):537-45.
Source: PubMed

ABSTRACT The activity and intracellular localization of protein kinase C (PKC) family members are controlled by phosphorylation at three highly conserved sites in the catalytic kinase domain. In the case of the novel PKCepsilon isoform, these are Thr(566) in the activation loop, Thr(710) in the turn motif and Ser(729) in the C-terminal hydrophobic motif. In the present study, we analysed the contribution of the phosphoinositide-dependent kinase 1 (PDK-1) and PKCepsilon kinase activity in controlling the phosphorylation of Thr(566) and Ser(729). In NIH 3T3 fibroblasts, PKCepsilon migrated as a single band, and stimulation with platelet-derived growth factor resulted in the appearance of a second band with a slower electrophoretic mobility, concomitant with an increase in phosphorylation of Thr(566) and Ser(729). Cells transfected with an active PDK-1 allele also resulted in increased PKCepsilon Thr(566) and Ser(729) phosphorylation, whereas an active myristoylated PKCepsilon mutant was constitutively phosphorylated at these sites. Protein kinase-inactive mutants of PKCepsilon were not phosphorylated at Ser(729) in cells, and phosphorylation of this site leads to dephosphorylation of the activation-loop Thr(566), an effect which can be reversed with either okadaic acid or co-transfection with active PDK-1. In vitro, PDK-1 catalysed the phosphorylation of purified PKCepsilon in the presence of mixed micelles containing either diacylglycerol or PtdIns(3,4,5)P(3), concomitant with an increase in Ser(729) phosphorylation. These studies reveal that the mechanism of phosphorylation of a novel PKC is the same as that for conventional PKCs: PDK-1 phosphorylation of the activation loop triggers autophosphorylation of the hydrophobic motif. However, the regulation of this phosphorylation is different for novel and conventional PKCs. Specifically, the phosphorylation of novel PKCs is regulated rather than constitutive.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Targeting the actin cytoskeleton (CSK) of cancer cells offers a valuable strategy in cancer therapy. There are a number of natural compounds that interfere with the actin CSK, but the mode of their cytotoxic action and, moreover, their tumor-specific mechanisms are quite elusive. We used the myxobacterial compound Chondramide as a tool to first elucidate the mechanisms of cytotoxicity of actin targeting in breast cancer cells (MCF7, MDA-MB-231). Chondramide inhibits cellular actin filament dynamics shown by a fluorescence-based analysis (fluorescence recovery after photobleaching (FRAP)) and leads to apoptosis characterized by phosphatidylserine exposure, release of cytochrome C from mitochondria and finally activation of caspases. Chondramide enhances the occurrence of mitochondrial permeability transition (MPT) by affecting known MPT modulators: Hexokinase II bound to the voltage-dependent anion channel (VDAC) translocated from the outer mitochondrial membrane to the cytosol and the proapoptotic protein Bad were recruited to the mitochondria. Importantly, protein kinase C-ɛ (PKCɛ), a prosurvival kinase possessing an actin-binding site and known to regulate the hexokinase/VDAC interaction as well as Bad phosphorylation was identified as the link between actin CSK and apoptosis induction. PKCɛ, which was found overexpressed in breast cancer cells, accumulated in actin bundles induced by Chondramide and lost its activity. Our second goal was to characterize the potential tumor-specific action of actin-binding agents. As the nontumor breast epithelial cell line MCF-10A in fact shows resistance to Chondramide-induced apoptosis and notably express low level of PKCɛ, we suggest that trapping PKCɛ via Chondramide-induced actin hyperpolymerization displays tumor cell specificity. Our work provides a link between targeting the ubiquitously occurring actin CSK and selective inhibition of pro-tumorigenic PKCɛ, thus setting the stage for actin-stabilizing agents as innovative cancer drugs. This is moreover supported by the in vivo efficacy of Chondramide triggered by abrogation of PKCɛ signaling shown in a xenograft breast cancer model.
    Cell Death & Disease 08/2014; 5:e1398. DOI:10.1038/cddis.2014.363 · 5.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes is a complex syndrome which leads to multiple dysfunctions including vascular disorders. Protein kinase C (PKC) and Rho-associated coiled-coil kinase (ROCK) are important regulatory enzymes mediating signal transduction in a number of vascular functions, including vascular smooth muscle contractility. Many studies have shown that vascular smooth muscle contractile responses are dramatically enhanced in diabetes where in, PKC and ROCK significantly contribute to the process by mediating Ca2+ sensitization of contractile proteins. Both PKC- and ROCK-mediated pathways converge to phosphorylate the inhibitory protein CPI-17 which binds to myosin light chain phosphatase (MLCP) and inhibits its activity. Besides, ROCK phosphorylates myosin light chain phosphatase targeting subunit 1 (MYPT1) which also inhibits the phosphatase activity. Inhibition of MLCP results in a higher level of myosin light chain phosphorylation for any given intracellular level of Ca2+ and activity of the myosin light chain kinase (MLCK). Ca2+ sensitization of smooth muscle, thus, could potentially maintain vascular contraction in diabetes. A link between the ROCK and PKC pathways in diabetic vascular smooth muscle cells has been shown, assuming that the ROCK and RhoA protein are downstream effectors of PKC. Furthermore, collected data suggest that PKC and ROCK are potential therapeutic targets for treating diabetes-related complications in vascular smooth muscle cells. Keywords: Diabetes; Protein kinase C; Rho kinase; Ca2+ sensitization; Vascular smooth muscle; Vascular tone
  • Source


Available from